-
Beam Therapeutics Inc. (BEAM $21.03)
- $21.03 Cap: $2.01B
- View BEAM Profile
- View Questions on BEAM
Detailed Quote
Questions on this company?
Become a Member
Company Profile
{tplLang.businessdescription | toLang tLang}
{ profileData.description }
{tplLang.details | toLang tLang}
{tplLang.ceo | toLang tLang}
{profileData.profile.details.ceo}
{tplLang.employees | toLang tLang}
{profileData.profile.details.employees | numeraljs '0,0'}
{tplLang.issuetype | toLang tLang}
{profileData.profile.details.issuetype | asIssueType}
{tplLang.industryclassifications | toLang tLang}
{tplLang.sector | toLang tLang}
{profileData.profile.classification.sector}
{tplLang.industry | toLang tLang}
{profileData.profile.classification.industry}
{tplLang.toolname| toLang tLang}
There is no {tplLang.toolname| toLang tLang} currently available for
{data.symbolstring}.
Interactive Chart
Key Ratios
Earnings
Analyst Recommendations
5i Recent Questions
-
Block Inc. Class A (SQ)
- P/E (TTM): 59.56X Cap: $53.89B
- View SQ Profile
- View Questions on SQ
-
Tesla Inc. (TSLA $328.49)
- $328.49 P/E (TTM): 181.13X Cap: $1.05T
- View TSLA Profile
- View Questions on TSLA
-
Exact Sciences Corporation (EXAS $48.36)
- $48.36 Cap: $9.12B
- View EXAS Profile
- View Questions on EXAS
-
Roku Inc. (ROKU $91.69)
- $91.69 Cap: $13.44B
- View ROKU Profile
- View Questions on ROKU
-
Teladoc Health Inc. (TDOC $8.33)
- $8.33 Cap: $1.46B
- View TDOC Profile
- View Questions on TDOC
-
CRISPR Therapeutics AG (CRSP $65.33)
- $65.33 Cap: $5.64B
- View CRSP Profile
- View Questions on CRSP
-
Intellia Therapeutics Inc. (NTLA $12.63)
- $12.63 Cap: $1.30B
- View NTLA Profile
- View Questions on NTLA
-
Zoom Communications Inc. (ZM $74.48)
- $74.48 P/E (TTM): 22.48X Cap: $22.53B
- View ZM Profile
- View Questions on ZM
-
Beam Therapeutics Inc. (BEAM $21.03)
- $21.03 Cap: $2.01B
- View BEAM Profile
- View Questions on BEAM
-
UiPath Inc. Class A (PATH $12.45)
- $12.45 Cap: $6.66B
- View PATH Profile
- View Questions on PATH
Q: Hi Peter,
I am not a big fan of ARKK or Cathie Wood. On a year-to-date basis, ARKK has fallen more than 50%. But I am fascinated with Cathie’s all or nothing investment approach. ARKK invests in disruptive technology firms. Her high risk and high reward investment style reminds me of Pete ‘Maverick’ Mitchell in the movies Top Gun and Top Gun Maverick. You either reach Mach 10 or crash and burn!
My question for your team relates to ARKK’s top ten holdings: ZM, TSLA, ROKU, CRSP, EXAS, TDOC, PATH, NTLA, SQ, and BEAM. Which of these stocks have fallen sufficiently so that a high-risk investor can safely purchase them for a five-to-ten-year hold? Also, what is your ranking of these ten high tech disruptive companies? Living life in the “danger zone” has its attractions.
Thanks,
George
I am not a big fan of ARKK or Cathie Wood. On a year-to-date basis, ARKK has fallen more than 50%. But I am fascinated with Cathie’s all or nothing investment approach. ARKK invests in disruptive technology firms. Her high risk and high reward investment style reminds me of Pete ‘Maverick’ Mitchell in the movies Top Gun and Top Gun Maverick. You either reach Mach 10 or crash and burn!
My question for your team relates to ARKK’s top ten holdings: ZM, TSLA, ROKU, CRSP, EXAS, TDOC, PATH, NTLA, SQ, and BEAM. Which of these stocks have fallen sufficiently so that a high-risk investor can safely purchase them for a five-to-ten-year hold? Also, what is your ranking of these ten high tech disruptive companies? Living life in the “danger zone” has its attractions.
Thanks,
George
-
CRISPR Therapeutics AG (CRSP $65.33)
- $65.33 Cap: $5.64B
- View CRSP Profile
- View Questions on CRSP
-
Twist Bioscience Corporation (TWST $34.77)
- $34.77 Cap: $2.08B
- View TWST Profile
- View Questions on TWST
-
Beam Therapeutics Inc. (BEAM $21.03)
- $21.03 Cap: $2.01B
- View BEAM Profile
- View Questions on BEAM
Q: Hello team,
Of the 3 companies above, BEAM has 3 times more shares sold short (18% of the float) but all three have been on a run.
If you could buy only one which one would you choose today as a great company for a long-term hold and which one you would rather avoid? And of course why?
Thanks for making investment accessible for ordinary people.
Of the 3 companies above, BEAM has 3 times more shares sold short (18% of the float) but all three have been on a run.
If you could buy only one which one would you choose today as a great company for a long-term hold and which one you would rather avoid? And of course why?
Thanks for making investment accessible for ordinary people.
-
Beam Therapeutics Inc. (BEAM $21.03)
- $21.03 Cap: $2.01B
- View BEAM Profile
- View Questions on BEAM
Q: On Oct 1, Beam Therapeutics announced an equity offering priced at $23.50/share; over the following days, the share price declined to as low as $22.24, i.e., below the offering price, though not as low as would reflect the dilutive effect of the new shares.
Yet today shares traded as high as $34.38; what, if anything, can we infer from this disconnect? Who would pay so much when new shares can be had at 2/3 the price?
Yet today shares traded as high as $34.38; what, if anything, can we infer from this disconnect? Who would pay so much when new shares can be had at 2/3 the price?
Insiders
Share Information
SEC Filings
News and Media